TG Therapeutics completes FDA filing for Roche challenger in CLL

TG Therapeutics completes FDA filing for Roche challenger in CLL

Source: 
Pharmaforum
snippet: 

TG Therapeutics has completed its rolling FDA filing for its U2 combination therapy consisting of the antibody ublituximab with the oral drug Ukoniq (umbralisib) as a treatment for chronic lymphocytic leukaemia (CLL).